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he issue of stent thrombosis (ST) and particularly late
tent thrombosis (LST) (30 days after deployment) (1)
as recently haunted the use of stents.
Although it occurs in bare-metal stents, LST is slightly
ore frequent in drug-eluting stents (DES), with an ap-
roximate 0.5%/year increased rate over bare-metal stents
ith a persistent risk for several years (2). The manifestation
f LST is myocardial infarction (MI) or death with a case
atality rate as high as 45% (3).
See page 383
There are numerous risk factors for LST but currently
ew answers. Among the many variables studied, patient
haracteristics for LST include the presence of diabetes (3),
enal failure (3), and thiopyridine resistance or discontinu-
tion (4). Lesion factors include small vessels (4), long stent
engths (5), increased total stent length (5), and bifurcation
isease (6). Procedural factors include incomplete stent
pposition or underexpansion of stents (7) and the use of
bifurcation stenting” techniques (8). Other proposed fac-
ors include delayed stent endothelization (9) and hypersen-
itivity to a DES component, such as the polymer (10).
The paper in this issue of JACC: Cardiovascular Interven-
ions by Suh et al. (11) documents that, when stents 31.5
m in length are used, there is increased risk of LST, MI,
nd death. They studied 3,145 patients who had DES
laced and followed them for a mean 29.6 months. It was
ound that, among the studied variables, stent lengths
31.5 mm were strongly associated with rates of ST 
.0%, death  5.2%, and MI  2.4%, as compared with
tents 31.5 mm, which had rates of ST  0.7%, death 
.0%, and MI  0.7%. Indeed, of the 68 patients who
eveloped ST, 60 (88%) had stent lengths 31.5 mm.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.From the Cardiac Catheterization Laboratory, Skokie Hospital, North Shore
niversity Health System, Skokie, Illinois.atients who had LST had received nearly 1 year of
hiopyridine therapy. They noted that the event rates were
ower in DES patients compared with patients who received
imilarly long bare-metal stents.
The risk of stent length has been previously documented
y Moreno et al. (5), who noted in a meta-analysis of 10
tudies that stent length was positively correlated with ST
ut—unlike Suh et al.—did not arrive at a threshold.
Unfortunately, there are no data on strategies to reduce
he risk of LST, and none of the current studies propose
uch strategies. Many of the risk factors for LST are not
odifiable (diabetes, renal insufficiency, small vessels);
ence, we need to focus on strategies for the modifiable risk
actors that might reduce LST. Certainly, there is a profile
f high-risk patients that we are aware of, which now
ncludes use of long stents. There are some strategies,
lthough unproven but intuitively appropriate, that can be
pplied in practice that might contribute to reduction of
ST, including:
. If possible, avoid using super long stents (31.5mm);
. Consider, when possible, to “spot stent” long lesions; the
use of intravascular ultrasound might be helpful to locate
minimally diseased areas;
. The liberal use of intravascular ultrasound after long
stent deployment might identify areas of incomplete
stent apposition requiring further expansion;
. In any high-risk patient (including long stents), consid-
eration of prolonged thiopyridine treatment of at least 2
years and in many cases indefinite use of thiopyridine.
The solution to LST has not been obvious, but attention
o modifiable risk factors such as super long stents as
emonstrated by Suh et al. (11) might serve to identify those
t risk and attempt to reduce the incidence of LST.
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